Drugs / CC-96673
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04860466 | Jan 2022 → Jul 2024 | non-Hodgkin lymphoma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-96673 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04860466 ↗ |
| Route | Intravenous | “IV Infusion” NCT04860466 ↗ |